The non-canonical NF-kappaB pathway in survival and function of T lymphocytes

T 淋巴细胞存活和功能中的非经典 NF-kappaB 通路

基本信息

  • 批准号:
    8261672
  • 负责人:
  • 金额:
    $ 38.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-05-01 至 2016-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): In lymphocytes, signals from antigen, cytokine, and innate immune receptors cause immediate, transient activation of NF-:B through the canonical pathway by triggering IkB degradation. A second, non-canonical or "alternative" NF-kB pathway has been described downstream of some members of the TNFR family. Slow, sustained activation of NF-kB through this IkB-independent, NIK-dependent non-canonical pathway governs the formation of secondary lymphoid organs (downstream of LT2R) and determines the fate of B cells (downstream of BAFFR). Almost nothing is known of the role of the non-canonical NF-kB pathway in T cell function, although T cells express a number of costimulatory TNFR family members, including OX40, 4-1BB, CD27, GITR, CD30, and HVEM, that have been shown to activate the non-canonical pathway in transfected cell lines, and that are known to provide essential signals for function and survival of activated T cells after antigen recognition. The working hypothesis of this proposal is that sustained activation of NF-kB through the non-canonical pathway downstream of these TNFR family members is necessary for induction and maintenance of expression of the cytokines, cytokine receptors, and anti-apoptotic proteins that allow T cells to survive and function as differentiated effector and memory cells. The proposed experiments are designed to determine whether the non-canonical pathway is activated downstream of the costimulatory TNFR family members in T cells, whether it is necessary for the costimulatory activity of TNFR family members in vivo, and whether independent activation of that pathway mimics some of the costimulatory activities of the TNFR family members, including blocking the function of regulatory T cells. PUBLIC HEALTH RELEVANCE: This grant application proposes to test the idea that a particular intracellular signaling pathway (the non- canonical NF-kB pathway) is necessary in T cells after they see their antigen to allow them to survive and function. Activation of this pathway in T cells could serve as an early biomarker for effective vaccines and a method to reverse T cell unresponsiveness in chronic infections and cancer immunotherapy. Inhibition of this pathway by drugs acting specifically on enzymes in this pathway (IKK1 and/or NIK) has the potential to block ongoing immune reactions that are dependent on internal danger signals resulting from inflammation and tissue damage, such as allergy, autoimmune disease, transplant rejection, and graft-versus-host disease, without blocking immunity to infectious agents driven by antigen receptors and innate receptors for microbial products through a related pathway (the canonical NF-kB pathway) and other signaling pathways.
描述(由申请人提供):在淋巴细胞中,来自抗原、细胞因子和先天免疫受体的信号通过典型途径触发IkB降解,引起NF-:B的立即、短暂激活。第二种非规范或“替代”NF-kB通路已在一些TNFR家族成员的下游被描述。NF-kB通过这种不依赖于ikb、依赖于nik的非典型途径缓慢、持续地激活,控制次级淋巴器官(LT2R的下游)的形成,并决定B细胞(BAFFR的下游)的命运。尽管T细胞表达了许多共刺激TNFR家族成员,包括OX40、4-1BB、CD27、GITR、CD30和HVEM,但人们对非规范NF-kB通路在T细胞功能中的作用几乎一无所知,这些成员已被证明可以激活转染细胞系中的非规范通路,并且已知它们在抗原识别后为活化T细胞的功能和存活提供必要的信号。该建议的工作假设是,通过这些TNFR家族成员下游的非规范途径,NF-kB的持续激活对于诱导和维持细胞因子、细胞因子受体和抗凋亡蛋白的表达是必要的,这些细胞因子、细胞因子受体和抗凋亡蛋白允许T细胞存活并作为分化效应细胞和记忆细胞发挥作用。本实验旨在确定非规范通路是否在T细胞共刺激TNFR家族成员下游被激活,是否为体内TNFR家族成员共刺激活性所必需,以及该通路的独立激活是否模拟TNFR家族成员的某些共刺激活性,包括阻断调节性T细胞的功能。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID C PARKER其他文献

DAVID C PARKER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID C PARKER', 18)}}的其他基金

The non-canonical NF-kappaB pathway in survival and function of T lymphocytes
T 淋巴细胞存活和功能中的非经典 NF-kappaB 通路
  • 批准号:
    8460461
  • 财政年份:
    2011
  • 资助金额:
    $ 38.5万
  • 项目类别:
The non-canonical NF-kappaB pathway in survival and function of T lymphocytes
T 淋巴细胞存活和功能中的非经典 NF-kappaB 通路
  • 批准号:
    8186294
  • 财政年份:
    2011
  • 资助金额:
    $ 38.5万
  • 项目类别:
The non-canonical NF-kappaB pathway in survival and function of T lymphocytes
T 淋巴细胞存活和功能中的非经典 NF-kappaB 通路
  • 批准号:
    8653526
  • 财政年份:
    2011
  • 资助金额:
    $ 38.5万
  • 项目类别:
Inflammation and T Lymphocyte Immunoregulation
炎症与T淋巴细胞免疫调节
  • 批准号:
    8050670
  • 财政年份:
    2009
  • 资助金额:
    $ 38.5万
  • 项目类别:
Inflammation and T Lymphocyte Immunoregulation
炎症与T淋巴细胞免疫调节
  • 批准号:
    7904050
  • 财政年份:
    2009
  • 资助金额:
    $ 38.5万
  • 项目类别:
Inflammation and T Lymphocyte Immunoregulation
炎症与T淋巴细胞免疫调节
  • 批准号:
    7695102
  • 财政年份:
    2009
  • 资助金额:
    $ 38.5万
  • 项目类别:
B Cell Subsets as Antigen-presenting Cells in Peripheral Self-tolerance
B 细胞亚群作为外周自我耐受中的抗原呈递细胞
  • 批准号:
    7364592
  • 财政年份:
    2007
  • 资助金额:
    $ 38.5万
  • 项目类别:
The Alternative NFkB Pathway in Survival and Function of Anti-Viral T Cells
抗病毒 T 细胞存活和功能中的替代 NFkB 途径
  • 批准号:
    7487426
  • 财政年份:
    2007
  • 资助金额:
    $ 38.5万
  • 项目类别:
B Cell Subsets as Antigen-presenting Cells in Peripheral Self-tolerance
B 细胞亚群作为外周自我耐受中的抗原呈递细胞
  • 批准号:
    7266093
  • 财政年份:
    2007
  • 资助金额:
    $ 38.5万
  • 项目类别:
The Alternative NFkB Pathway in Survival and Function of Anti-Viral T Cells
抗病毒 T 细胞存活和功能中的替代 NFkB 途径
  • 批准号:
    7391936
  • 财政年份:
    2007
  • 资助金额:
    $ 38.5万
  • 项目类别:

相似海外基金

Development of back bone vectors for chimeric antigen receptors against key molecules, CD47 and CD24, activating macrophages
开发针对关键分子 CD47 和 CD24 的嵌合抗原受体的骨干载体,激活巨噬细胞
  • 批准号:
    23K06728
  • 财政年份:
    2023
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Engineering synthetic adhesion receptors to enhance the sensitivity of therapeutic chimeric antigen receptors
工程合成粘附受体以增强治疗性嵌合抗原受体的敏感性
  • 批准号:
    MR/W031353/1
  • 财政年份:
    2022
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Research Grant
CAREER: Engineering next-generation chimeric antigen receptors for cancer immunotherapy using phospho-proteomics
职业:利用磷酸蛋白质组学设计用于癌症免疫治疗的下一代嵌合抗原受体
  • 批准号:
    2145853
  • 财政年份:
    2022
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Continuing Grant
Construction of a drug discovery platform utilizing antigen receptors that regulate the quality of cancer immunity
利用调节癌症免疫质量的抗原受体构建药物发现平台
  • 批准号:
    22K06603
  • 财政年份:
    2022
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
  • 批准号:
    10701754
  • 财政年份:
    2022
  • 资助金额:
    $ 38.5万
  • 项目类别:
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
  • 批准号:
    10557760
  • 财政年份:
    2022
  • 资助金额:
    $ 38.5万
  • 项目类别:
Molecualr imaging for development of chimeric antigen receptors (CARs) resistant to T cell exhaustion
用于开发抗 T 细胞耗竭的嵌合抗原受体 (CAR) 的分子成像
  • 批准号:
    20H03536
  • 财政年份:
    2020
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Chimeric antigen receptors on regulatory T cells as a treatment strategy in auto-immune diseases.
调节性 T 细胞上的嵌合抗原受体作为自身免疫性疾病的治疗策略。
  • 批准号:
    437200
  • 财政年份:
    2020
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Studentship Programs
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
  • 批准号:
    10542442
  • 财政年份:
    2020
  • 资助金额:
    $ 38.5万
  • 项目类别:
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
  • 批准号:
    9922602
  • 财政年份:
    2020
  • 资助金额:
    $ 38.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了